Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-05-24
Chart by TradingView
6/9
Piotroski F — financial health
5.08
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$4.6B
P / E77.2×
P / S6.7×
P / B8.0×
P / FCF33.4×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M |
| Operating cash flow | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M |
| Shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M |
| Ratios | |||||
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% |
| FCF margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% |
| Return on assets | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% |
| Return on equity | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% |
| Current ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 |
| Revenue growth | 60.1% | 56.6% | 22.7% | 471.2% | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.08 (safe)
- Working capital / assets 0.508
- Retained earnings / assets -0.605
- EBIT / assets 0.101
- Equity / liabilities 2.896
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001730430 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.